Sector News

Bristol-Myers teams with BioMotiv to build and buy biotechs

September 5, 2019
Life sciences

Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv before going on to acquire them outright once a preclinical candidate is identified.

BioMotiv, a biotech accelerator associated with the $380 million Harrington Project for Discovery & Development, builds companies around academic science and helps these startups get into human testing and on to deals with larger partners. In the future, Bristol-Myers may step in partway through that process and buy the biotechs.

The agreement makes Bristol-Myers a limited partner in BioMotiv. In that capacity, Bristol-Myers will work with BioMotiv to spawn new biotechs, providing additional funding to choice projects along the way. In some cases, Bristol-Myers will acquire a startup at pre-agreed terms during preclinical.

BioMotiv CEO Ted Torphy sees Bristol-Myers bringing more than just money to the relationship.

“This new partnership will allow us to leverage the extensive expertise of Bristol-Myers Squibb across multiple disease areas,” Torphy said. “Combined with BioMotiv’s unique model and focus on accelerating breakthrough discoveries from leading academic institutions, we have the opportunity to make a real impact on the lives of patients.”

The agreement comes about three years after Bristol-Myers teamed up with a BioMotiv portfolio company, Dual Therapeutics. That deal saw Bristol-Myers pay an undisclosed upfront fee and commit to more than $255 million in milestones for the chance to license small molecules that block multiple cancer pathways, such as those that promote growth and survival.

Dual Therapeutics has since fallen off the radar—its web address is now unclaimed—but the model that brought it into the world continues to pump out new biotechs. Most of BioMotiv’s portfolio plays have relatively low profiles, but some have made headlines. Orca Pharmaceuticals, for example, formed a deal with AstraZeneca worth up to $122.5 million in 2015.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach